M344: Potent HDAC Inhibitor with IC50 100 nM for Cancer and HIV-1 Research

Executive Summary: M344, supplied by APExBIO, is a cell-permeable histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM, demonstrating robust efficacy in neuroblastoma, medulloblastoma, and breast cancer cell lines (Brumfield et al., 2025). It induces histone acetylation and cell cycle arrest, leading to apoptosis even in p53-deficient models. M344 enhances responses to radiation and chemotherapeutic agents while showing low off-target toxicity in preclinical models. The compound also activates HIV-1 LTR gene expression, supporting its use in latency reversal research (APExBIO). It is soluble in DMSO and ethanol but not in water, with recommended concentrations ranging from 1–100 μM for 1–7 days of treatment.

Biological Rationale

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails, leading to chromatin condensation and transcriptional repression (Brumfield et al., 2025). Aberrant HDAC activity is implicated in oncogenesis, promoting cell proliferation and blocking apoptosis. In neuroblastoma, high HDAC expression correlates with advanced tumor stage and poor prognosis. HDAC inhibitors, such as M344, reverse these effects by increasing histone acetylation, restoring the expression of tumor suppressor genes, and promoting cell differentiation. This epigenetic modulation forms the basis for HDAC inhibitor use in cancer and viral latency research. For additional context on HDAC signaling pathways, see this systems-biology review, which is extended here with new efficacy data and dosing insights.

Mechanism of Action of M344

M344 is a small-molecule HDAC inhibitor that binds to the catalytic domain of class I and II HDACs, blocking the deacetylation of histone and non-histone proteins. This results in increased acetylation of histone H3 and H4, relaxation of chromatin, and upregulation of genes involved in cell cycle arrest (e.g., p21) and apoptosis (e.g., Puma). Uniquely, M344 can induce pro-apoptotic factors via p53-independent pathways. It also modulates the transcription factor NF-κB, impacting gene expression in both cancer and HIV-1 latency models. M344's cell permeability allows for rapid intracellular accumulation at effective concentrations (≥1 μM).

Evidence & Benchmarks

• M344 inhibits HDAC activity with an IC50 of 100 nM in in vitro enzymatic assays (APExBIO).
• M344 induces G0/G1 cell cycle arrest and caspase-mediated apoptosis in neuroblastoma cell lines (Brumfield et al., 2025, DOI).
• In MCF-7 breast cancer, medulloblastoma (D341 MED), and neuroblastoma (CH-LA 90) cells, the GI50 values for M344 are approximately 0.63–0.65 μM (APExBIO).
• Combination of M344 with topotecan or cyclophosphamide reduces tumor rebound and improves tolerability in vivo (Brumfield et al., 2025, DOI).
• M344 enhances radiation-induced cytotoxicity in human squamous carcinoma cell lines SCC-35 and SQ-20B (APExBIO).
• M344 activates HIV-1 LTR gene expression, supporting its use in HIV-1 latency reversal (APExBIO).
• Compared to vorinostat, M344 displays stronger cytostatic and migration-inhibitory effects in neuroblastoma models (Brumfield et al., 2025, DOI).

Applications, Limits & Misconceptions

M344 is widely used in oncology and virology research. Its main applications include:

• Cell-based assays for apoptosis and cell cycle arrest
• Preclinical models of breast cancer, neuroblastoma, and medulloblastoma
• Enhancement of chemotherapy and radiotherapy responses
• Epigenetic modulation of gene expression in HIV-1 latency models

For stepwise workflows and troubleshooting, refer to this lab guide; the present article updates it with new in vivo synergy data and storage recommendations.

Common Pitfalls or Misconceptions

• M344 is not soluble in water; use DMSO or ethanol as solvents as per product documentation (APExBIO).
• Not suitable for diagnostic or therapeutic use in humans; intended strictly for research purposes.
• Long-term storage in solution form is discouraged; prepare fresh aliquots and store at -20°C as a solid.
• M344 does not reverse all forms of drug resistance; its efficacy is context-dependent and may vary by cell line and combination agent.
• Activity is not universal for all cancers or viral strains; always validate in the specific model system.

Workflow Integration & Parameters

M344 (SKU A4105) is delivered as a solid and should be dissolved in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL, with ultrasonic treatment). Typical working concentrations for cell-based assays are 1–100 μM, with treatment durations from 1 to 7 days. For optimal stability, store the solid at -20°C and avoid repeated freeze-thaw cycles. Shipping is on blue ice to preserve product integrity. M344 is intended for in vitro research only and is not certified for clinical or diagnostic applications. For protocol integration, see the scenario-driven guidance in this application note; this article clarifies recent updates in storage and combination therapy strategies.

Conclusion & Outlook

M344 is a well-validated, potent HDAC inhibitor with robust effects on cell differentiation, apoptosis, and tumor suppression in preclinical models. Its nanomolar IC50, cell permeability, and demonstrated synergy with chemotherapeutic agents position it as a reference compound for cancer epigenetics and HIV-1 latency research. Future work will further delineate its clinical translation and potential in combination therapies. For product specifications or to order, refer to the official APExBIO M344 product page.